{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:47:00Z","timestamp":1715586420139},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.leukres.2010.09.021","type":"journal-article","created":{"date-parts":[[2010,10,23]],"date-time":"2010-10-23T08:18:33Z","timestamp":1287821913000},"page":"36-37","source":"Crossref","is-referenced-by-count":7,"title":["Cardiotoxicity of imatinib: At the heart of the problem"],"prefix":"10.1016","volume":"35","author":[{"given":"Mario","family":"Tiribelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Medeot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.09.021_bib0005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2010.09.021_bib0010","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2010.09.021_bib0015","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Eng J Med"},{"key":"10.1016\/j.leukres.2010.09.021_bib0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2010.09.021_bib0025","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","article-title":"Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies","volume":"34","author":"Wolf","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.09.021_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2010.09.021_bib0035","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.09.021_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0107-15a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Rosti","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2010.09.021_bib0045","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","article-title":"Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005","volume":"43","author":"Verweij","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2010.09.021_bib0050","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cncr.24683","article-title":"Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate","volume":"116","author":"Trent","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2010.09.021_bib0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nm0207-224","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019","volume":"13","author":"Gambacorti-Passerini","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.leukres.2010.09.021_bib0060","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.leukres.2007.08.016","article-title":"Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: a single institution experience","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.09.021_bib0065","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21157","article-title":"Brain natriuretic peptide level as marker of cardiac function in imatinib-treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy","volume":"83","author":"Tiribelli","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2010.09.021_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2010.07.011","article-title":"The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia","author":"Marcolino","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.09.021_bib0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","article-title":"A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib","volume":"35","author":"Estabragh","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2010.09.021_bib0080","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.leukres.2010.09.021_bib0085","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610004698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610004698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T18:46:06Z","timestamp":1711910766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610004698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0145212610004698"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.09.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}